Pembrolizumab, Decitabine +/- Venetoclax
Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 54 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- BCL-2 Inhibitor, Checkpoint Inhibitor, Hypomethylating Agents (HMA), Monoclonal Antibody, Programmed Death Receptor-1 (PD-1), Doublet Therapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1516
- NCT Identifier
- NCT03969446
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.